|
|
| |
What does the name PreMD mean?
 |
| PreMD Inc. is a name we created to describe the role we believe our products fulfill: predicting disease at an early stage in order to prevent its progressing— or from occurring at all. “Pre,” when combined with “MD,” suggests self-management and monitoring of one’s health. PreMD reflects our focus on empowering patients and doctors alike to better manage health and wellness. |
| Back to Top |
What are the company’s ticker symbols on the Toronto Stock Exchange and American Stock Exchange?
|
| Our symbol on the Toronto Stock Exchange is PMD. On the American Stock Exchange it is PME. |
| Back to Top |
Will I need to exchange my old IMI stock certificates for new PreMD stock certificates?
|
| No. Your IMI stock certificates are still valid and will continue to be honored by the company. If you wish to change your IMI stock certificates to PreMD stock certificates, please contact Equity Transfer at (416) 361-0152 ext. 221. |
| Back to Top |
How much stock does management own?
|
| Management of PreMD, including the Board of Directors, owns approximately 20% of the company’s total shares outstanding. |
| Back to Top |
Which mutual funds and institutions own PreMD shares?
|
| Mutual funds and pension funds change their holdings regularly and report them at the end of each quarter. Holders of PreMD’s shares currently include AGF Management Ltd., I.G. Investment Management, GWL Investment Management, Harris Investment Management and Suffolk Capital Management, among others. |
| Back to Top |
What analysts follow PreMD?
|
| Click here for more information on analyst coverage. |
| Back to Top |
Does PreMD have any preferred shares or options that trade?
|
| No. |
| Back to Top |
Does PreMD pay a dividend?
|
| No. PreMD does not yet have earnings to yield a dividend. |
| Back to Top |
When does PreMD report its quarterly earnings results?
|
| PreMD’s quarterly reporting periods conclude at the end of March, June, September and December. PreMD reports first, second and third quarter results within 45 days following each quarter end; fiscal year-end results are reported within 90 days of year end. The expected reporting dates are listed on the Event Calendar. |
| Back to Top |
What are the most comparable companies to PreMD in North America?
|
| PreMD’s business model and focus on non-invasive, predictive tests is unique and the company has no direct competitors. However, companies that share similar attributes include Exact Sciences, Cholestech Corp., Quidel Corp., OraSure Technologies and Inverness Medical Innovations. |
| Back to Top |
Who is PreMD’s transfer agent?
|
PreMD’s transfer agent is Equity Transfer Services:
120 Adelaide Street West
Suite 420
Toronto, Ontario
Canada
M5H 4C3
Tel: 416.361.0152 ext. 221
Fax: 416.361.0470
Email: info@equitytransfer.com |
| Back to Top |
Where can I obtain a copy of PreMD’s investor package and annual or quarterly reports?
|
| PreMD’s annual and quarterly reports are available elsewhere on this website in electronic form. You can also request copies of PreMD’s annual report, quarterly reports, or other investor information by email, or by calling 416.222.3449. |
| Back to Top |
How many of PreMD’s products are approved for sale?
|
PREVU* Point of Care (POC) Skin Sterol Test, PreMD’s lead cardiovascular product, has been cleared for sale in the U.S., Canada and Europe. The company has developed two additional formats of this test, a lab-processed format, known as PREVU* LT Skin Sterol Test, which is cleared for sale in Canada and Europe, and a consumer, or home, test, known as PREVU* PT Skin Sterol Test, currently in development.
|
| Back to Top |
Does PreMD have a strategic partner for its cancer products?
|
| PreMD is currently evaluating partnering opportunities for its cancer portfolio. |
| Back to Top |
When do you expect LungAlert™, ColorectAlert™ and the breast cancer test to be approved?
|
All three products are in clinical trials. There are many steps that a company must follow before achieving regulatory approval, and each one must be carefully planned and executed.
We expect that we may be in a position to initiate the regulatory process for LungAlert™ in 2007, with ColorectAlert™and our breast cancer test following thereafter. |
| Back to Top |
